[go: up one dir, main page]

NO20043457L - 3- (imidazolyl) -2-alkoxypropanoic acids as TAFIA inhibitors - Google Patents

3- (imidazolyl) -2-alkoxypropanoic acids as TAFIA inhibitors

Info

Publication number
NO20043457L
NO20043457L NO20043457A NO20043457A NO20043457L NO 20043457 L NO20043457 L NO 20043457L NO 20043457 A NO20043457 A NO 20043457A NO 20043457 A NO20043457 A NO 20043457A NO 20043457 L NO20043457 L NO 20043457L
Authority
NO
Norway
Prior art keywords
imidazolyl
tafia inhibitors
alkoxypropanoic
acids
alkoxypropanoic acids
Prior art date
Application number
NO20043457A
Other languages
Norwegian (no)
Inventor
David John Bull
Mark Edward Bunnage
Charlotte Moira Norfo Allerton
Robert John Maguire
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20043457L publication Critical patent/NO20043457L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20043457A 2002-01-22 2004-08-19 3- (imidazolyl) -2-alkoxypropanoic acids as TAFIA inhibitors NO20043457L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids
PCT/IB2003/000060 WO2003061652A1 (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors

Publications (1)

Publication Number Publication Date
NO20043457L true NO20043457L (en) 2004-08-19

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043457A NO20043457L (en) 2002-01-22 2004-08-19 3- (imidazolyl) -2-alkoxypropanoic acids as TAFIA inhibitors

Country Status (24)

Country Link
EP (1) EP1467731A1 (en)
JP (1) JP2005520811A (en)
KR (1) KR20040077775A (en)
CN (1) CN1620291A (en)
AP (1) AP2004003084A0 (en)
AR (1) AR038197A1 (en)
BR (1) BR0307016A (en)
CA (1) CA2472238A1 (en)
EA (1) EA200400716A1 (en)
EC (1) ECSP045200A (en)
HR (1) HRP20040659A2 (en)
IL (1) IL162677A0 (en)
IS (1) IS7310A (en)
MA (1) MA27167A1 (en)
MX (1) MXPA04006573A (en)
NO (1) NO20043457L (en)
OA (1) OA12756A (en)
PA (1) PA8563501A1 (en)
PE (1) PE20030929A1 (en)
PL (1) PL371487A1 (en)
TN (1) TNSN04121A1 (en)
TW (1) TW200302094A (en)
UY (1) UY27615A1 (en)
WO (1) WO2003061652A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
EP1874322A1 (en) * 2005-04-18 2008-01-09 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
CA2741783A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having tafia inhibitory activity
JP2012511008A (en) * 2008-12-05 2012-05-17 持田製薬株式会社 Morpholinone compounds as factor IXa inhibitors
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
US8946443B2 (en) 2010-03-18 2015-02-03 Daiichi Sankyo Company, Limited Cyclopropanecarboxylic acid derivative
KR101704095B1 (en) * 2010-03-18 2017-02-09 다이이찌 산쿄 가부시키가이샤 Cycloalkyl-substituted imidazole derivative
CN105263928A (en) 2013-06-10 2016-01-20 赛诺菲 Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as medicines
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES
NZ763299A (en) 2017-09-14 2025-09-26 Daiichi Sankyo Co Ltd Compound having cyclic structure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (en) * 1999-05-03 1999-05-03 Astra Ab New compounds
MXPA03001425A (en) * 2000-08-17 2003-06-06 Pfizer PHARMACEUTICAL COMPOUNDS.

Also Published As

Publication number Publication date
WO2003061652A8 (en) 2004-09-10
TW200302094A (en) 2003-08-01
ECSP045200A (en) 2004-08-27
EA200400716A1 (en) 2004-12-30
WO2003061652A1 (en) 2003-07-31
IS7310A (en) 2004-06-14
UY27615A1 (en) 2003-08-29
OA12756A (en) 2006-07-03
CA2472238A1 (en) 2003-07-31
MXPA04006573A (en) 2004-10-04
PE20030929A1 (en) 2003-11-05
MA27167A1 (en) 2005-01-03
JP2005520811A (en) 2005-07-14
HRP20040659A2 (en) 2004-10-31
BR0307016A (en) 2004-11-03
EP1467731A1 (en) 2004-10-20
IL162677A0 (en) 2005-11-20
KR20040077775A (en) 2004-09-06
TNSN04121A1 (en) 2006-06-01
PA8563501A1 (en) 2004-08-31
PL371487A1 (en) 2005-06-13
CN1620291A (en) 2005-05-25
AR038197A1 (en) 2005-01-05
AP2004003084A0 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
DK2130537T3 (en) N3-alkylated benzimidazole derivatives as MEK inhibitors
CY2016042I2 (en) NEW HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMAS INHIBITORS
DK1492785T3 (en) 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors
DK1311488T3 (en) Substituted imidazoles as tafia inhibitors
DK1663232T3 (en) Benzimidazole derivatives as human chymase inhibitors
DK1586319T3 (en) Thiadiazolidinones as GSK-3 inhibitors
NO20055680D0 (en) Hexahydropyridoisoquinolines as DPP-IV inhibitors
DE60320933D1 (en) RHO-KINASE INHIBITORS
DK1789041T3 (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
ATE505471T1 (en) AZAINDOL KINASE INHIBITORS
NO20044654L (en) Piperidinoylpiperidines as 5-HTIF agonists
NO20043642L (en) Heterocyclic tripeptides such as hepatitis C inhibitors
NO20050665L (en) Pyrrolidone derivatives as MAOE inhibitors
DK1603570T3 (en) AMINOHETEROARYL COMPOUNDS AS PROTEINKINASE INHIBITORS
DK1585749T3 (en) Diazepinoindole derivatives as kinase inhibitors
DK1797042T3 (en) Indozolone derivatives as 11B-HSD1 inhibitors
DE602004018837D1 (en) PTIDASE-IV INHIBITORS
DK1740569T3 (en) Imidazole derivatives as TAF1α inhibitors
ATE545642T1 (en) MMP INHIBITORS
NO20043457L (en) 3- (imidazolyl) -2-alkoxypropanoic acids as TAFIA inhibitors
DE60301419D1 (en) packaging
NO20043610L (en) Phenylpyrimidinamines as IgE inhibitors
DK1487802T3 (en) 2,3-diaryl-pyrazolidine derivatives as neurotensin-degrading enzyme inhibitors
DE50310603D1 (en) splitter basement
ZA200405344B (en) 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application